Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5V2HR
|
|||
| Drug Name |
IBI188
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | |
| Company |
Innovent Biologics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen CD47 (CD47) | Target Info | Blocker | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04511975) A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Innovent Biologics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.